Posting fresh info about MS, for people with MS and their supporters

  • HOT off the AAN 2011 Press: 23% Lower Relapse Rate For MS Patients On Laquinimod

    Multiple sclerosis patients on laquinimod experienced a 23% reduction in annual relapse rate compared to those on a placebo during a two year Phase III clinical trial [...]

    • Teva completes enrollment in second Phase III trial

      Jun 26, 2009 (Datamonitor via COMTEX) — Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, and Active Biotech, a Swedish pharmaceutical company, have completed patient enrollment for [...]

      • Hot off the AAN Press: Laquinimod, New Data, Novel MOA

        New Data Illustrate Novel Mechanism OF Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis -Researchers Demonstrate Immunomodulatory Effects of Laquinimod on Disease Activity [...]

        • The Age of Orals: Who Will Win the Race to the Market?

          Jan 23, 2009 Oral Cladribine Reduces MS Relapses in Phase 3 Clinical Trial Oral cladribine (EMD Serono) reduced the relapse rate significantly more than inactive placebo in [...]

          • MS Oral Drug Laquinimod Begins Phase III Trials

            JERUSALEM & LUND, Sweden–Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) today announced that the companies are initiating a clinical Phase III [...]



SUPPORT / Find out More



aan, alemtuzumab, avonex, betaseron, biogen, bioms medical corp, campath, ccsvi, cis, cladribine, clarity, cognitive dysfunction, copaxone, daclizumab, dirucotide, discovery, ectrims, elan, fampridine-sr, fatigue, fda, fda fast track status, fingolimod, fty-720, genzyme, gilenia, gilenya, interferons, laquinimod, merck, merck/serono, novartis, oral ms therapies, phase iii, pml, rebif, rrms, serono, smoking, spms, stem cells, teriflunomide, teva, therapy, tysabri


Follow me on Twitter
Friend me on Facebook
Subscribe by Email

Bookmark and Share

Wordpress Engine. Upstart Theme. Better Project.